[go: up one dir, main page]

MX2015008329A - Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. - Google Patents

Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.

Info

Publication number
MX2015008329A
MX2015008329A MX2015008329A MX2015008329A MX2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A
Authority
MX
Mexico
Prior art keywords
fusion partners
listerial
expression
preparation
methods
Prior art date
Application number
MX2015008329A
Other languages
English (en)
Inventor
Peter M Lauer
Marcella Fasso
Dirk Brockstedt
Thomas W Dubensky
William G Hanson
Skoble Justin
Leong Meredith Lai Ling
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of MX2015008329A publication Critical patent/MX2015008329A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona ácidos nucleicos, sistemas de expresión, y cepas de vacuna que proporcionan una expresión y secreción eficientes de antígenos de interés en el citosol de las células huésped, y respuestas efectivas de las células T CD4 y CD8 mediante la vinculación funcional de Listerial y otros péptidos señal bacterial/acompañantes de secreción como compañeros de fusión de terminal N en el marco de lectura transaccional con los antígenos de proteína codificados recombinantes. Estos compañeros de fusión terminal N se eliminan (ya sea por eliminación real, por mutación o por combinación de estos enfoques) para cualquiera de las secuencias nativas PEST a la secuencia, y/o para ciertos residuos hidrofóbicos.
MX2015008329A 2012-12-27 2013-12-27 Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. MX2015008329A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US201361780744P 2013-03-13 2013-03-13
PCT/US2013/078119 WO2014106123A1 (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
MX2015008329A true MX2015008329A (es) 2016-03-01

Family

ID=51017446

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008329A MX2015008329A (es) 2012-12-27 2013-12-27 Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.

Country Status (12)

Country Link
US (2) US9663557B2 (es)
EP (1) EP2938627B1 (es)
JP (2) JP2016503655A (es)
KR (1) KR102160322B1 (es)
CN (1) CN104955835B (es)
AU (2) AU2013370210B2 (es)
BR (1) BR112015015076A2 (es)
CA (1) CA2888727A1 (es)
EA (1) EA201590397A8 (es)
MX (1) MX2015008329A (es)
SG (2) SG10201700916SA (es)
WO (1) WO2014106123A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
MX2017000857A (es) 2014-07-18 2017-10-11 Advaxis Inc Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
CN107709548B (zh) 2015-02-06 2022-06-28 新加坡国立大学 用于增强治疗性免疫细胞的功效的方法
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
EA201792274A1 (ru) * 2015-04-13 2018-02-28 Адуро Биотек, Инк. Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
UY36617A (es) * 2015-04-13 2016-10-31 Aduro Biotech Inc Proteínas de fusión inmunogénicas para el tratamiento del cáncer
EP3838918B1 (en) * 2015-05-18 2022-08-31 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
HUE060396T2 (hu) * 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei
US10550183B2 (en) 2016-11-22 2020-02-04 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
JP2020530291A (ja) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
US11179339B2 (en) 2017-09-19 2021-11-23 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
EP3694532B1 (en) 2017-10-10 2025-02-26 Gritstone bio, Inc. Neoantigen identification using hotspots
WO2019104203A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
CN112074737A (zh) 2018-03-09 2020-12-11 阿德瓦希斯公司 用于评估李斯特菌菌株的减毒和感染性的组合物和方法
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
US12129485B2 (en) 2018-05-23 2024-10-29 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
JP2023532444A (ja) 2020-06-23 2023-07-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド・ア・ボディ・コーポレイト 呼吸器病原体を診断し、ｃｏｖｉｄ－１９に関連する転帰を予測する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
CA2404164A1 (en) * 2000-03-29 2001-10-04 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US20020150588A1 (en) 2000-09-21 2002-10-17 Allison James P. SPAS-1 cancer antigen
AU2003240971A1 (en) 2002-05-29 2003-12-19 Univ California Attenuated listeria spp. and methods for using the same
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
AU2004281834A1 (en) 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
ES2532942T3 (es) * 2006-03-01 2015-04-06 Aduro Biotech Listeria obtenida por ingeniería genética y métodos de uso de la misma
US20080124354A1 (en) 2006-07-10 2008-05-29 Yvonne Paterson Methods for administering tumor vaccines
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
AU2009249273A1 (en) * 2008-05-19 2009-11-26 Aduro Biotech Compositions comprising PrfA*mutant listeria and methods of use thereof
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
HUE039747T2 (hu) 2010-11-17 2019-02-28 Aduro Biotech Inc Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
WO2012125551A1 (en) * 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment

Also Published As

Publication number Publication date
BR112015015076A2 (pt) 2018-10-30
EP2938627A4 (en) 2016-12-14
EP2938627A1 (en) 2015-11-04
CN104955835B (zh) 2020-04-17
AU2013370210A1 (en) 2015-06-18
WO2014106123A8 (en) 2016-06-16
AU2013370210A8 (en) 2016-06-23
CN104955835A (zh) 2015-09-30
JP2016503655A (ja) 2016-02-08
EA201590397A1 (ru) 2016-02-29
US9663557B2 (en) 2017-05-30
JP2018135355A (ja) 2018-08-30
EA201590397A8 (ru) 2016-08-31
US20170253637A1 (en) 2017-09-07
SG10201700916SA (en) 2017-03-30
KR20150099738A (ko) 2015-09-01
CA2888727A1 (en) 2014-07-03
AU2013370210B2 (en) 2018-06-14
US20140186387A1 (en) 2014-07-03
EP2938627B1 (en) 2019-03-20
KR102160322B1 (ko) 2020-09-25
AU2018203555A1 (en) 2018-06-07
SG11201502792TA (en) 2015-05-28
JP6671408B2 (ja) 2020-03-25
WO2014106123A1 (en) 2014-07-03
HK1215260A1 (zh) 2016-08-19

Similar Documents

Publication Publication Date Title
MX2015008329A (es) Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
WO2009130618A3 (en) Flagellin polypeptide vaccines
WO2011140284A3 (en) Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
MY173004A (en) Mycobacterial antigen vaccine
EP2772265A3 (en) Recombinant HCMV and RHCMV vectors and uses thereof
NZ753307A (en) Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
WO2013151706A3 (en) Subunit vaccine delivery platform for robust humoral and cellular immune responses
NZ745324A (en) Vaccines and vaccine components for inhibition of microbial cells
EA201791806A1 (ru) Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
MX2017000838A (es) Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas.
WO2020065349A8 (en) Vaccines and methods
Badell et al. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells
MY202196A (en) Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
NZ725212A (en) Group a streptococcus vaccine
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
NZ760008A (en) Uti fusion proteins
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
Wang et al. Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B
Sharma et al. Mycobacterium indicus pranii protein MIP_05962 induces Th1 cell mediated immune response in mice
IN2013CN01528A (es)
EP2488197A4 (en) TH1 / TH2 POLARIZING VACCINES
WO2012178078A3 (en) Use of yscf, truncated yscf and yscf homologs as adjuvants